HOME >> MEDICINE >> NEWS
Anti-inflammatory drug's potentially deadly side effect found to be rare

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

The new study found no new cases of progressive multifocal leukoencephalopathy (PML) and confirmed the three previously identified cases of PML associated with use of the drug. One fatal and one nonfatal case of PML occurred in a trial using natalizumab as a multiple sclerosis treatment; a second fatality happened in a trial that used the drug to treat patients with Crohn's disease, an inflammatory bowel disorder.

"Our analysis suggests about one in every1,000 people who took natalizumab contracted this disease; however, there weren't enough patients exposed to the drug to allow us to precisely estimate the risk, which could be as low as one in 5,000 or as high as one in 300," says senior author David Clifford, M.D., the Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology at Washington University School of Medicine in St. Louis.

The results of the study, along with two separate studies of natalizumab's effectiveness as an MS treatment, are published in this week's issue of The New England Journal of Medicine.

The brand name of natalizumab, which was jointly developed by Biogen and Elan Pharmaceuticals, is Tysabri. The drug is a monoclonal antibody that binds to inflammatory immune T cells and prevents them from crossing membranes that protect the brain and the central nervous system. Prior to the studies that were halted last year, earlier studies showed a 66 percent reduction in the rate of relapses in MS patients treated with the natalizumab, which has to be injected on a monthly basis.

Clifford predicts that his group's report and the other studies of natalizumab will be important elements in "lively" discussions to be held by the Food and Drug Administration reg
'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
1-Mar-2006


Page: 1 2 3 4

Related medicine news :

1. Anti-inflammatory drug prevents liver cancer in at-risk liver patients
2. Anti-inflammatory drugs following hip replacement surgery could harm rather than help
3. Anti-inflammatory function of Alzheimers disease drugs revealed
4. A drugs brand name skews patient treatment choices
5. Chemical maps hint at drugs effects on schizophrenia
6. Study to test drugs potential to preserve insulin production in newly diagnosed type 1 diabetics
7. Trial demonstrates new drugs effectiveness against psoriasis
8. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
9. STAMP system can help professionals to identify potentially violent individuals
10. Women with breast cancer do not get potentially life-saving information, survey reveals
11. U-M study finds some prostate cancer patients potentially overtreated

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti inflammatory drug potentially deadly side effect found rare

(Date:8/1/2014)... (HealthDay News) -- Almost 140 people die every ... the United States. But there are several ... Gardner, injury prevention coordinator at Cincinnati Children,s Hospital ... a medical center news release. "As families ... it,s important for parents and children to go ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... bisexual, and transgender individuals who want to conceive a ... their heterosexual and cisgendered peers, such as reduced fertility, ... and legal challenges to become parents. A comprehensive review ... is presented in the article " LGBT Assisted Reproduction: ... LGBT Health , a peer-reviewed journal from ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
Breaking Medicine News(10 mins):Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
(Date:7/31/2014)... 2014 Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2014. Cash and investments in ... compared to $309.1 million at March 31, 2014."The second half ... we look forward to significant milestones for a number of ... Chief Executive Officer of Nektar. "The first of these is ...
(Date:7/31/2014)...  UBM Medica US announces that Cancer ... presents exclusive slide shows dealing with communication in the ... care. Cancer Network, the online ... blogs, and podcasts about the latest clinical findings. Among ... , End-of-life care is challenging for even the ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
Cached News: